Four Years for a Pill That Was Never His: Parikshit Somani and the Shadow of Trimetazidine

Hai Phong, just past one in the morning. The email from the International Tennis Integrity Agency ran to a few lines: a 26-year-old Indian player named Parikshit Somani banned for four years. The substance was trimetazidine. I read it three times, then opened the list of cases that had involved the same molecule. When Kamila Valieva's name appeared, I knew I would not sleep.

The distance between Somani and Valieva is the entire width of sport. Valieva stepped onto the Beijing ice in 2026 under the lenses of hundreds of broadcasters, aged 15. Somani plays doubles, peaked at No. 256, and competes at events where the stands are emptier than the practice court. One heart medication, one defence, one four-year ban.

Somani's positive sample was collected at a lower-tier event in Astana, Kazakhstan, in 2026. Based on my experience following matches at indoor hard-court tournaments, the stands at events like this are so empty that the ball echo carries further than the crowd. He argued that food prepared by a family member had been contaminated by that relative's medication. An independent tribunal heard the case in August and concluded that the food-contamination theory was "scientifically implausible", "highly speculative" and "unconvincing". The ban runs until September 2029. During that period Somani cannot play, cannot coach, and cannot attend any event organised by World Tennis, the WTA, the ATP, the Grand Slams or any national federation.

I used to run the 800 metres. That event taught me something every ranking table hides: speed over the first 400 metres says nothing about whether you can still stand upright over the last 200. World No. 256 in men's tennis is the same. It does not measure where a person wakes up, what they eat, or how much they can pay a lawyer when the anti-doping letter arrives. Nguyen Thi Oanh is not a name — she is a life still running forward. So is anyone ranked 256.

Trimetazidine treats angina. It works by pushing muscle cells to shift energy production away from fatty acids and toward glucose, helping tissue spare oxygen when blood supply is poor. For an endurance athlete, that property is hard to ignore. The World Anti-Doping Agency added the substance to the prohibited list in 2026. That same year, Chinese swimming star Sun Yang received a three-month ban for trimetazidine — a number so short it has almost been swallowed by history. Valieva made the substance a global headline. Then in 2026, international media reported that 23 Chinese swimmers had returned positive samples for trimetazidine, in a case handled quietly and closed with a contamination explanation.

Four cases. One decade. One molecule.

What holds my attention is the repetition of the defence, not the substance itself. Valieva spoke of a strawberry dessert her grandfather left on the table. Somani spoke of food cooked at home. The swimmers spoke of contaminated food in a hotel. Three settings, three cultures, one identical template — and that template is why tribunals have hardened.

The core sits in pharmacokinetics. Trimetazidine has a short half-life of roughly seven hours, and its detection window usually stretches only one to two days past the final dose. For a deliberate user, that means stopping a few days before competing. For a contaminated athlete, it means one wrong meal on the day of collection. Two completely different states of intent, leaving almost identical traces in the tube.

Put another way, this is one of the few molecules forensic science cannot use to separate guilt from bad luck. Every verdict therefore rests on something else: the quality of evidence the accused brings to the table.

And that is where the system starts to tilt.

In recent years some cases have ended without sanction because the athlete proved the contamination route through hair testing, batch analysis of supplements, or detailed pharmacokinetic modelling. Those files run to hundreds of pages, produced by independent laboratories, and the cost often exceeds a full year's income for a player ranked outside the top 200. I have followed a few similar hearings, and what struck me was not the law but the invoice.

The tribunal in Somani's case did not say he lied. It said he failed to prove it. Morally that is a different sentence; practically it produces the same result: four years.

There is a detail most reports skip. Trimetazidine is generic, cheap, and sold widely in India, China, Russia and much of Eastern Europe. It sits in the medicine cabinets of countless households with elderly relatives. If you live in a three-generation apartment where your grandmother takes heart pills every morning, kitchen contamination is a real hypothesis, not theatre.

Here is the paradox: the contamination defence is at once the most common explanation in doping cases and the hardest one to prove — and those two properties reinforce each other.

The counterintuitive point I want to place on the table: the problem is not that athletes lie more often. The problem is that the system chose a substance it cannot police fairly.

WADA applies minimum reporting levels to certain substances to avoid cases built on a few stray molecules in urine. For trimetazidine, that threshold still leaves a wide grey zone. Inside that grey zone, outcomes depend on whether you can afford an expert.

Look at the power structure. Tennis has the ITIA, which investigates and publishes decisions with reasonable transparency. Athletics has the Athletics Integrity Unit with its own procedures. Swimming passes through continental federations. Each body applies different thresholds, speeds and attitudes to the same molecule. An athlete heavily sanctioned in one sport can be treated leniently in another, with chemically identical samples.

That asymmetry is not a technical flaw. It is a design.

And it manufactures a class of athlete I call the 256s: good enough to be tested, not rich enough to defend themselves. Somani belongs to that group. Valieva, at 15, belonged to it in another way — placed at the centre of a machine she did not control, and handed the same four-year sanction.

One phrase in the Somani ruling made me pause. The panel used "scientifically implausible". In legal English that is heavy language. It does not merely say the evidence is weak. It says the hypothesis is, given current knowledge, close to impossible. Yet current knowledge about trimetazidine in food still has gaps, and anti-doping technical documents have conceded as much.

I am not saying Somani is innocent. I do not have the data to say that, and I do not publish before verifying. I am saying that a system claiming to rest on science has an obligation to publish its own level of certainty.

My old laptop still runs. It is slow, it overheats, and it forces me to type slower than I think. That laptop taught me: slow does not mean late, it just means telling the story a different way. A four-year ban deserves the same reading — slow, careful, and with no skipping of the hardest part.

An arena is not big because of the seats; it is big because of the stories that choose to stay. Parikshit Somani's story will stay in the ITIA file until September 2029. The question I carry into sleep tonight is not whether he took the pill. It is this: if a Vietnamese player ranked 700 is named for trimetazidine tomorrow, who pays to prove he ate the wrong meal?